zur Navigation zum Inhalt
Onkologie 10. Februar 2009

New treatment options for the management of non-Hodgkin lymphoma

Although the outcome of patients with non-Hodgkin lymphoma (NHL) has, in general, improved significantly over years, treatment failure due to drug resistance remains a problem. Recently, the focus of drug development has shifted from conventional cytotoxic drugs to agents directed against specific molecular targets and immunotherapy. This has mainly been driven by advances in the understanding of the molecular pathogenesis of NHL. A large number of promising new agents are in preclinical and clinical development. The challenge for clinicians is how best to incorporate them into already existing treatment regimes. This review will highlight some recent clinical trials focussing on targeted small molecules and monoclonal antibodies in NHL.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben